Menu
Back to Journals » Cancer Management and Research » Volume 15
A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma [Corrigendum]
Liu Y, Sheng L, Hua H, Zhou J, Zhao Y, Wang B. Cancer Manag Res. 2023;15:651–666.
The authors have advised Table 2 on pages 654-656, is incorrect. The correct Table 2 is as follows.
 |
Table 2 Baseline characteristics of patients |
Page 663, Figure 6 caption, the text “(D) OS of BCL2 ≥50%; (E) OS of MYC ≥40%” should read “(D) OS of MYC ≥40%; (E) OS of BCL2 ≥50%”.
The authors apologize for these errors and advise they do not affect the results of the paper.
© 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.